Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

Open access
Singanayagam, Aran, Glanville, Nicholas, Girkin, Jason L., Ching, Yee Man, Marcellini, Andrea, Porter, James D., Toussaint, Marie, Walton, Ross P., Finney, Lydia J., Aniscenko, Julia, Zhu, Jie, Trujillo-Torralbo, Maria-Belen, Calderazzo, Maria Adelaide, Grainge, Chris, Loo, Su-Ling, Veerati, Punnam Chander, Pathinayake, Prabuddha S., Nichol, Kristy S., Reid, Andrew T., James, Phillip L., Solari, Roberto, Wark, Peter A. B., Knight, Darryl A., Moffatt, Miriam F., Cookson, William O., Edwards, Michael R., Mallia, Patrick, Bartlett, Nathan W., Johnston, Sebastian L. · 2018 · Nature Communications

Abstract

Inhaled corticosteroids (ICS) have limited efficacy in reducing chronic obstructive pulmonary disease (COPD) exacerbations and increase pneumonia risk, through unknown mechanisms. Rhinoviruses precipitate most exacerbations and increase susceptibility to secondary bacterial infections. Here, we show that the ICS fluticasone propionate (FP) impairs innate and acquired antiviral immune responses leading to delayed virus clearance and previously unrecognised adverse effects of enhanced mucus, impaired antimicrobial peptide secretion and increased pulmonary bacterial load during virus-induced exacerbations. Exogenous interferon-β reverses these effects. FP suppression of interferon may occur through inhibition of TLR3- and RIG-I virus-sensing pathways. Mice deficient in the type I interferon-α/β receptor (IFNAR1−/−) have suppressed antimicrobial peptide and enhanced mucin responses to rhinovirus infection. This study identifies type I interferon as a central regulator of antibacterial immunity and mucus production. Suppression of interferon by ICS during virus-induced COPD exacerbations likely mediates pneumonia risk and raises suggestion that inhaled interferon-β therapy may protect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04574-1

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 196

Metadata

Authors
Singanayagam, A., Glanville, N., Girkin, J. L., Ching, Y. M., Marcellini, A., Porter, J. D., Toussaint, M., Walton, R. P., Finney, L. J., Aniscenko, J., Zhu, J., Trujillo-Torralbo, M.-B., Calderazzo, M. A., Grainge, C., Loo, S.-L., Veerati, P. C., Pathinayake, P. S., Nichol, K. S., Reid, A. T., James, P. L., Solari, R., Wark, P. A. B., Knight, D. A., Moffatt, M. F., Cookson, W. O., Edwards, M. R., Mallia, P., Bartlett, N. W., & Johnston, S. L.
Venue
Nature Communications
Published
2018-06-08
Volume
9
Issue
1
Pages
2229-2229
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2806885108
Cited by
196
References
10
FWCI
18.26
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. https://app.cochat.ai/papers/10.1038/s41467-018-04574-1
The paper
Singanayagam, A., Glanville, N., Girkin, J. L., Ching, Y. M., Marcellini, A., Porter, J. D., Toussaint, M., Walton, R. P., Finney, L. J., Aniscenko, J., Zhu, J., Trujillo-Torralbo, M.-B., Calderazzo, M. A., Grainge, C., Loo, S.-L., Veerati, P. C., Pathinayake, P. S., Nichol, K. S., Reid, A. T., . . . Johnston, S. L. (2018). Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nature Communications. https://doi.org/10.1038/s41467-018-04574-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.